Eupraxia Pharmaceuticals Inc. Common Stock (EPRX PINK) stock market data APIs

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates include EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis, and a product candidate intended for intra-articular use; PROMENADE, which is in a Phase III clinical trial of knee OA patients to evaluate the safety and efficacy of single and repeat doses of EP-104IAR; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. EP-104 consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). The company is also involved in the development of product candidates for oncology.SPRINGBOARD is in a Phase II double-blind, placebo-controlled clinical study (protocol EP-104IAR-201) that assesses the efficacy, safety, and pharmacokinetics (PK) of EP-104IAR. Additionally, EP-104IAR is in a Phase I double-blind, placebo-controlled clinical study (protocol EP-104-101) to assess safety, PK, and preliminary efficacy. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.